Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-1: Mirikizumab in Moderate-to-Severe Plaque Psoriasis
2017-003298-32Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Mirikizumab arm with Placebo arm (2 arms). Primary endpoints: Static Physician’s Global Assessment (sPGA) response at Week 16 and PASI 90 at Week 16. Started Mar 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2017-003298-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003298-32.